Group 1 - Independent director Peng Long of New Hope, Yuandong Bio, and Digital China is under investigation for serious violations of discipline and law [1][2] - Peng Long has held various academic and administrative positions, including professor and doctoral supervisor at Southwest University of Finance and Economics [1] - In 2024, Peng Long received pre-tax compensation of 100,000 yuan from New Hope, 240,000 yuan from Yuandong Bio, and 132,800 yuan from Digital China [2] Group 2 - All three companies confirmed that Peng Long only performed duties at the board level and did not participate in specific business operations [2] - New Hope stated that Peng Long "does not participate in the daily management of the company" [2] - Digital China and Yuandong Bio emphasized that his responsibilities "do not involve the daily operations of the company" [2]

Policy Developments - The National Healthcare Security Administration (NHSA) is soliciting public opinions on the draft adjustment plan for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, as well as the commercial health insurance innovative drug catalog [2] - The first version of the commercial health insurance innovative drug catalog will be established in 2025, focusing on innovative drugs with high clinical value that cannot be included in the basic catalog [2] Drug and Device Approvals - JinSai Pharmaceutical's monoclonal antibody drug, Firsekibart, has been approved for the treatment of acute gouty arthritis in adults who are intolerant to or have contraindications for non-steroidal anti-inflammatory drugs and/or colchicine [4] - Betta Pharmaceuticals' innovative drug, Tazemetostat, has been approved for the treatment of locally advanced or metastatic breast cancer in adults who have progressed after endocrine therapy [5] - Xiansheng Pharmaceutical's monoclonal antibody, Suweisitabant, has been approved for the treatment of recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in adults who have received no more than one prior systemic therapy [6] Capital Markets - Merida Biosciences, a U.S. biotech company, has raised $121 million in Series A financing, setting a record for Series A funding in the autoimmune field [8] Industry Events - Former Takeda China President, Dan Guohong, will join BeiGene as General Manager for Greater China, Central Asia, and South Asia, starting August 18, 2025 [10] - Yuan Dong Bio's independent director, Peng Long, is under disciplinary review and investigation for serious violations of discipline and law [12] - KangLe WeiShi announced that its shareholder, Tianlangxing Holdings Group, has reduced its holdings by 1.6953 million shares, accounting for 0.6034% of the company's total share capital [13]

Core Viewpoint - The independent director Peng Long of New Hope, Yuandong Bio, and Digital China is under investigation for serious violations of discipline and law, but this situation is not expected to significantly impact the companies' operations [1][2]. Group 1: Company Announcements - New Hope announced that its independent director, Peng Long, is under investigation by the Central Commission for Discipline Inspection and the Shanxi Provincial Supervisory Commission, but his role does not involve daily management, thus not affecting the company's operations [1]. - Digital China also reported that Peng Long is under investigation, emphasizing that he does not participate in the company's daily operations, which will not have a significant impact on the company's business activities [1]. - Yuandong Bio confirmed that Peng Long is under investigation and reiterated that he does not engage in the company's daily management, ensuring that the investigation will not significantly affect the company's operations [2]. Group 2: Peng Long's Roles - Peng Long serves as an independent director and holds various committee positions in New Hope, including the Compensation and Assessment Committee, Risk Control Committee, and Nomination Committee [1][2]. - In Digital China, Peng Long is an independent director and a member of the Audit Committee and the Strategy and ESG Committee [1][2]. - At Yuandong Bio, he is the independent director, the chair of the Strategy Committee, and a member of the Nomination and Audit Committees [2].

作 者丨尹华禄 编 辑丨陈思颖 刘雪莹 7月2日晚间，新希望也发布公司独董被查公告并表示，彭龙系公司独立董事，目前除担任公 司独立董事、董事会薪酬与考核委员会委员、董事会风险控制委员会委员、董事会提名委员 会委员外，未担任公司其他职务，不参与公司日常经营管理。上述事项不会对公司生产经营 活动产生重大影响。 苑东生物今年4月发布的年报显示，彭龙曾任西南财经大学党委常委、常务副校长等职务，西 南财经大学金融学院教授。现任西南财经大学金融学院博士生导师、东南大学首席教授、经 济管理学院教授、博士生导师，全国金融专业学位研究生教育指导委员会委员、教育部高等 学校专业设置与教学指导委员会主任委员等职位。2023年5月起任苑东生物独立董事。 公开资料显示，彭龙于1964年出生，毕业于中国科学院系统科学研究所应用数学专业，获博 士学位。1999年起享受国务院政府特殊津贴，2014年入选国家百千万人才工程，被授予"国家 有突出贡献中青年专家"称号。 值得一提的是，彭龙此前曾任北京外国语大学校长。 苑东生物、新希望双双公告：独立董事出事！ 7月2日，创新药上市公司苑东生物（688513.SH）发布公告称，公司于昨日（7月1日） ...

Group 1 - The independent director of Yuan Dong Bio (688513.SH), Peng Long, is under investigation for serious violations of discipline and law, as announced on July 2 [1] - Peng Long holds multiple positions within the company, including independent director and chair of the board's strategic committee, but does not participate in daily operations [1] - The company asserts that this investigation will not have a significant impact on its production and operational activities [1] Group 2 - Peng Long has a notable academic background, having served as a professor and doctoral advisor at Southwest University of Finance and Economics and Southeast University [2] - He has held various prestigious positions, including being a member of the National Financial Professional Degree Graduate Education Steering Committee and the Director of the Ministry of Education's Higher Education Professional Setting and Teaching Guidance Committee [2] - Peng Long was born in 1964 and has received several accolades, including the State Council's special allowance and recognition as a national outstanding young and middle-aged expert [2] Group 3 - Prior to his current roles, Peng Long was the president of Beijing Foreign Studies University [3] - Information regarding Peng Long has been removed from the faculty listings of Southwest University of Finance and Economics and Southeast University [3]

证券代码：688513 证券简称：苑东生物 公告编号：2025-045 成都苑东生物制药股份有限公司 彭龙先生系公司独立董事，目前除担任公司第四届董事会独立董事、董事会 战略委员会主任委员（召集人）、董事会提名委员会委员、董事会审计委员会委 员外，未担任公司其他职务，不参与公司日常经营管理。上述事项不会对公司生 产经营活动产生重大影响。 公司将持续关注上述事项的后续情况，严格按照相关规定及时履行信息披露 义务，敬请广大投资者注意投资风险。 关于公司独立董事接受纪律审查和监察调查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于 2025 年 7 月 1 日通 过中共山西省纪律检查委员会、山西省监察委员会网站获悉，公司独立董事、教 育部原副厅级干部彭龙涉嫌严重违纪违法，目前正接受中央纪委国家监委驻教育 部纪检监察组纪律审查和临汾市监委监察调查。 成都苑东生物制药股份有限公司董事会 2025 年 7 月 3 日 1 特此公告。 ...

Group 1 - The company announced that independent director Peng Long is under investigation for serious violations of discipline and law by the Central Commission for Discipline Inspection and the Supervisory Commission of Linfen City [1] - Peng Long currently serves as the independent director of the company's fourth board, chairman of the board's strategic committee, member of the board's nomination committee, and member of the board's audit committee [1] - The company stated that this matter will not have a significant impact on its production and operational activities [1] Group 2 - The company will continue to monitor the progress of the event and will strictly adhere to information disclosure obligations as required [1]

Core Points - The company announced the first vesting results of the 2024 restricted stock incentive plan, with a total of 418,656 shares vested [1][10] - The shares for this vesting were sourced from the company's repurchase of its A-share common stock from the secondary market [9] Summary of Relevant Sections Decision-Making Process and Disclosure - On April 28, 2024, the company's board and supervisory board approved the draft of the 2024 restricted stock incentive plan and related proposals [2][3] - The plan was publicly disclosed on April 29, 2024, on the Shanghai Stock Exchange website [2] Vesting Details - The total number of shares granted was 1,046,640, with 418,656 shares vested, representing 40% of the granted shares [7] - The vesting included 180 individuals, with core technical personnel and other key employees being the main recipients [9] Stock Source and Structure Changes - The vested shares were sourced from the company's repurchased A-share common stock, meaning there was no change in the total share capital of the company [9] - The controlling shareholder's stake remained unchanged before and after the vesting [9] Verification and Registration - The company received a verification report from an accounting firm confirming the subscription funds for the vested shares, totaling approximately RMB 9.54 million [9][10] - The registration of the vested shares was completed on June 26, 2025, as confirmed by the China Securities Depository and Clearing Corporation [10]

Group 1 - The stock of Yuandong Biotech (688513) has a comprehensive score of 51.09, indicating a strong performance [1] - The current main cost is 40.70 CNY, with a 5-day main cost of 39.96 CNY, a 20-day main cost of 41.49 CNY, and a 60-day main cost of 36.93 CNY [1][2] - The stock has not experienced any limit-up or limit-down events in the past year [1] Group 2 - The stock price has broken through the short-term resistance level, suggesting a potential short-term strength, while the mid-term trend remains unclear [2] - The net inflow of main funds on June 27, 2025, was 13.76 million CNY, accounting for 7% of the total transaction volume [2] - The financial data shows earnings per share of 0.34 CNY, operating profit of 0.62 billion CNY, and a sales gross margin of 79.155% [3][2] Group 3 - The stock is associated with several industry sectors, including chemical pharmaceuticals (0.94%), infant and child concepts (0.71%), monoclonal antibodies (0.72%), and immunotherapy (1.10%) [4]

证券代码：688513 证券简称：苑东生物 公告编号：2025-044 成都苑东生物制药股份有限公司 第一个归属期归属结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司有关业务规则的规定，成都苑东生物制药股份有限公司（以下 简称"公司"）于 2025 年 6 月 27 日收到中国证券登记结算有限责任公司上海分公 司出具的《过户登记确认书》，完成了公司 2024 年限制性股票激励计划（以下简 称"本次激励计划"）首次授予第一个归属期归属的股份登记工作。现将有关情况 公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 （一）2024 年 4 月 28 日，公司召开的第三届董事会第十八次会议，审议通 过了《关于公司<2024 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2024 年限制性股票激励计划实施考核管理办法>的议案》及《关于提请股 东大会授权董事会办理公司 2024 年限制性股票激励计划有 ...